Drug Name: Augtyro
Active Ingredient: repotrectinib
Indication: To treat ROS1-positive non-small cell lung cancer
Approval Date: 11/15/2023
Company: Bristol-Myers Squibb Company
More: https://accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf